PTC Therapeutics plans to request approval for its GT-AADC gene therapy, developed for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency, in the United States. Supported by positive data from clinical studies, the company expects to submit a biologics license application (BLA) with the U.S. Food and Drug Administration…
News
Recent Posts
- Celebrating the 7th anniversary of our daughter’s ‘Reborn Day’
- AADC deficiency mutations may produce potentially harmful compound
- When a Halloween costume offers an important lesson on inclusion
- How we support our child while encouraging her independence
- Taking time for the unscheduled work of rare disease parenting